Mirae Asset Mutual Fund · Direct Growth · SEBI Category: Equity
Mirae Asset Healthcare Fund benefits from Mirae Asset's global research network — headquartered in Korea, the parent company has deep expertise in global healthcare investing including Korean bio-pharma, US specialty pharma and global medical technology. This global perspective supplements domestic Indian pharma research — providing insight into global drug pricing trends, FDA inspection patterns and healthcare technology disruptions that affect Indian healthcare companies.
The fund invests across the healthcare value chain — Indian pharmaceutical companies with US and emerging market exposure, domestic formulation companies, hospital chains and diagnostic companies benefiting from India's healthcare penetration growth. Vrijesh Kasera's research approach incorporates global sector trends alongside fundamental Indian company analysis.
Vrijesh Kasera is Fund Manager at Mirae Asset Mutual Fund and manages the Mirae Asset Healthcare Fund. He brings global healthcare sector research expertise supported by Mirae Asset's international investment network — providing perspective on global pharmaceutical trends, drug discovery pipelines and healthcare technology innovations that affect Indian healthcare companies and their competitive positioning.
For current co-manager details and full biography, refer to the latest Mirae Asset Mutual Fund factsheet on AMFI or the AMC website.
Informational points to help you form your own view — not judgements or recommendations.
Live data. Current fund highlighted. Click any fund name for full analysis.
| Fund | NAV | AAUM | 1Y Return | 3Y CAGR | 5Y CAGR | Sharpe (3Y) |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund | ₹596.02 | ₹7.9K Cr Jan–Mar 2026 | +5.9% | +22.5% p.a. | +13.4% p.a. | 1.37 |
| SBI Healthcare Opportunities Fund | ₹532.86 | ₹3.8K Cr Jan–Mar 2026 | +10.5% | +25.5% p.a. | +16.2% p.a. | 1.61 |
| DSP Healthcare Fund | ₹46.10 | ₹3.0K Cr Jan–Mar 2026 | +8.8% | +22.9% p.a. | +15.4% p.a. | 1.62 |
| Mirae Asset Healthcare Fund ▲ | ₹47.02 | ₹2.7K Cr Jan–Mar 2026 | +13.9% | +25.8% p.a. | +15.6% p.a. | 1.45 |
| HDFC Pharma and Healthcare Fund | ₹20.01 | ₹1.9K Cr Jan–Mar 2026 | +19.9% | — | — | — |
Calculated from 1,948 daily NAV records in RightAdvise DB. Last calculated: Jun 2026.
1M / 3M / 6M / 1Y — simple point-to-point return · 3Y / 5Y / 10Y — CAGR (compounded annual growth rate)
Based on all rolling windows in full NAV history. Dates show the start and end of each period.
Jan 1 to Dec 31 each year. Simple point-to-point — not CAGR.
Rolling returns show performance across every possible investment start date — not one cherry-picked number. Learn more →
How much the fund fell from its peak NAV — what investors actually experience during crashes. Calculated from full NAV history.
Calculated from actual NAV data. "Pre-inception" means the fund didn't exist during that period.
Calculated from 3 years of daily NAV — industry standard. Risk-free rate: 6.5% p.a. Last updated: Jun 2026. What do these mean? →
Our portfolio holdings page shows every stock the fund owns, sector allocation, and month-over-month changes — from official AMC disclosures.
See how Mirae Asset Healthcare Fund Direct Growth ranks against other Equity funds on returns, drawdown, Sharpe ratio and AAUM — side by side.
New fund analysis, articles and market insights — no spam, no selling. Unsubscribe anytime.
Found this useful? Share it
Found an error? Have a suggestion? We read every response.